FirmaIQ
Org.nr 985 889 635 2012 → 2013 Year-over-year analysis

LYTIX BIOPHARMA ASA: årsregnskap 2013 vs 2012

Fresh owner capital

approved 2014-06-11; registry 2014-09-22; journal 2014 849699

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2013 with 2012 for LYTIX BIOPHARMA ASA. Revenue 50.5k NOK → 50.2k NOK (-0.5%). Equity 17.95m NOK → 47.22m NOK.

On the constructive side: equity strengthened; cash rose; owners injected capital. Pressures included: revenue fell; operating result weakened.

Mixed year — gains and pressures both show up.

At a glance

Scorecard

Revenue
50.5k NOK 50.2k NOK
-0.5%
Operating result
-32.00m NOK -43.44m NOK
-35.8%
Equity
17.95m NOK 47.22m NOK
+163.0%
Cash
8.44m NOK 51.47m NOK
+510.0%
Total assets
24.83m NOK 58.09m NOK
+134.0%

What improved

  • ↑

    Equity strengthened

    Book equity 17.95m NOK → 47.22m NOK (equity ratio 72.3% → 81.3%). Calculated

  • ↑

    Cash rose

    Bank deposits 8.44m NOK → 51.47m NOK (+510.0% YoY). Calculated

  • ↑

    Owners injected capital

    Paid-in equity rose 17.95m NOK → 47.22m NOK (+29.26m NOK). Reported fact

What deteriorated

  • ↓

    Revenue fell

    Operating income / revenue moved from 50.5k NOK to 50.2k NOK (-0.5% YoY). Calculated

  • ↓

    Operating result weakened

    Operating result -32.00m NOK → -43.44m NOK (op. margin -63365.4% → -86449.1%). Calculated